WVP
NVCR icon

Worth Venture Partners’s NovoCure NVCR Stock Holding History

Worth Venture Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,400
Closed -$385K – 190
2023
Q1 		$385K Buy
+6,400
New +$511K 0.19% 96

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Worth Venture Partners's NVCR Position: Q2 2023 in Review

Worth Venture Partners sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 6,400 shares — an estimated $385K sold.

Worth Venture Partners first reported a position in NVCR in Q1 2023 and held it in 1 quarter. The position peaked at $385K in Q1 2023. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

  • Worth Venture Partners reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
  • Worth Venture Partners sold 6,400 NovoCure shares in Q2 2023, an estimated $385K.
  • Worth Venture Partners first reported a position in NovoCure in Q1 2023 and held it in 1 quarter.
  • Worth Venture Partners's NovoCure position peaked at $385K in Q1 2023.
  • 267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Worth Venture Partners's 13F filing for Q2 2023, filed 14 Aug 2023.